36 Український журнал нефрології та діалізу №3 (71) 2021 Ukrainian Journal of Nephrology and Dialysis, 3 (71)’2021 Оригінальні наукові роботи Original Papers Abstract. The present study aimed to evaluate the efficacy and safety of EMAVAIL (epoetin alfa) in the correction of anemia in hemodialysis patients. Methods. A total of 36 patients undergoing regular hemodialysis were enrolled in this prospective study. Among the patients were 19 (53%) men and 17 (47%) women with severe anemia (hemoglobin (Hb) level ≤ 90 g/L). The mean patients’ age was 48.41±1.82 years, an average dialysis vintage consisted of 42.38±10.41 months. All the patients had thrice-weekly hemodialysis sessions, with a mean duration of 12.6 ± 0.51 hours per week and Kt/V 1.27 ± 0.08. All the patients were treated with biosimilar of epoetin alfa EMAVAIL intravenously three times a week in adjustable doses. The follow-up period was 56 days. Results. At the study entry, the mean Hb level in hemodialysis patients was 81.7±0,93 g/L. In 56 days of anemia treatment, the concentration of Hb increased to 109.17±1.75 g/L. Eventually, 32 (89%) patients achieved the target Hb level (110 g/L); 6 (17%) patients had adverse events (mild hypertension). There were no serious adverse events. Conclusions. EMAVAIL is an effective and safe epoetin alfa biosimilar for anemia management in hemodialysis patients. Key words: chronic kidney disease, anemia, hemodialysis, epoetin alfa, hemoglobin. Conflict of interest statement. The authors declare no competing interest. © Dudar I., Krasjuk E., Honchar Yu., Loboda M., Shifris I., Krot V., Savchuk V., 2021. All rights reserved. Correspondence should be addressed to Iryna Dudar: irina_d@ukr.net Article history: Received February 26, 2021 Received in revised form June 27, 2021 Accepted June 28, 2021 Ukrainian Journal of Nephrology and Dialysis Scientific and Practical, Medical Journal Founders: • State Institution «Institute of Nephrology NAMS of Ukraine» • National Kidney Foundation of Ukraine ISSN 2304-0238; eISSN 2616-7352 Journal homepage: https://ukrjnd.com.ua Original Papers I. O. Dudar 1 , E. K. Krasjuk 2 , Y. I. Honchar 1 , O. M. Loboda 1 , I. M. Shifris 1 , V. F. Krot 1 , V. M. Savchuk 2 doi : 10.31450/ukrjnd.3(71).2021.05 The use of epoetin alfa biosimilar in the anemia management in hemodialysis patients 1 SI «Institute of Nephrology NAMS of Ukraine», Kyiv, Ukraine 2 MNE «Kyiv City Center of nephrology and dialysis», Kyiv, Ukraine Citation: Dudar I, Krasjuk E, Honchar Yu, Loboda M, Shifris I, Krot V, Savchuk V. The use of epoetin alfa biosimilar in the anemia management in hemodialysis patients. Ukr J Nephr Dial. 2021;3(71):36-43. doi: 10.31450/ukrjnd.3(71).2021.05.